美国扩大成人肺炎球菌疫苗接种建议至50岁及以上人群的成本效果分析
该研究比较了将成人肺炎球菌疫苗接种年龄从65岁提前至50岁的成本效果,采用单队列模型分析PCV20和PCV21两种疫苗策略。结果显示,单剂接种从65岁移至50岁虽降低50-64岁人群疾病负担但增加65岁及以上人群负担;50岁和65岁两剂接种改善健康结局但增加成本,PCV21在多数情景下价值更优。
要点
- 单剂接种从65岁移至50岁:PCV21的ICER为每损失一个QALY节省575,614美元,PCV20虽节省成本但健康结局更差。
- 50岁和65岁两剂接种改善所有健康结局但增加成本,PCV21的ICER为214,430美元/QALY,PCV20为546,811美元/QALY。
- PCV21在多数情景下比PCV20具有更有利的成本效果价值。
核心结论
- 常规肺炎球菌疫苗接种于50岁和65岁两剂可改善健康结局但增加成本。
- PCV21在多数情景下比PCV20产生更有利的价值。
研究设计与样本
- 单队列模型比较50岁接种与既往推荐(PCV20或PCV21),采用有限社会视角。
- 考虑策略:50岁单剂对比65岁单剂;50岁和65岁两剂对比65岁单剂。
- 模型纳入肺炎球菌疾病发病率、死亡率、疫苗效力、成本和QALY,并进行敏感性分析。
主要发现
- 将接种从65岁移至50岁降低50-64岁成人肺炎球菌疾病负担,但增加65岁及以上成人负担(PCV20和PCV21)。
- PCV21单剂从65岁移至50岁的ICER为每损失一个QALY节省575,614美元,反映成本降低但疾病负担增加。
- PCV20单剂从65岁移至50岁在每获得QALY的成本方面节省成本,但生命年、死亡、病例和住院结局更差。
- 50岁和65岁两剂接种改善所有健康结局但增加成本,PCV21的ICER为214,430美元/QALY,PCV20为546,811美元/QALY。
关键数值与推荐
- 单剂从65岁移至50岁:PCV21的ICER为每损失一个QALY节省575,614美元。
- 两剂50岁和65岁:PCV21的ICER为214,430美元/QALY,PCV20为546,811美元/QALY。
临床怎么用
- 决策者需权衡50岁接种对50-64岁人群的疾病负担降低与对65岁及以上人群负担增加。
- 若选择两剂接种策略,PCV21在多数情景下比PCV20更具成本效果价值。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Previously, the Advisory Committee on Immunization Practices (ACIP) recommended pneumococcal vaccines for adults aged 19-64 with risk conditions and for all adults aged ≥65. Licensure of 21-valent pneumococcal conjugate vaccine (PCV21) targeting pneumococcal serotypes that commonly cause disease in adults led to consideration of an age-based program for adults aged ≥50 to improve implementation feasibility and achieve broader population protection. METHODS: Vaccination at age 50 was compared to the previous recommendation using 20-valent or 21-valent pneumococcal conjugate vaccines (PCV20 or PCV21). Two strategies were considered: (1) a single dose at age 50 vs. a single dose at age 65; and (2) one dose at age 50 and a second dose at age 65 vs. one dose at age 65. The single cohort model included pneumococcal disease incidence, mortality, vaccine efficacy, costs, and quality-adjusted life-years (QALY), using a limited societal perspective. Sensitivity analyses were performed to assess the impact of uncertainty. RESULTS: Moving vaccination from age 65 to 50 years reduced pneumococcal disease burden among adults aged 50-64 years but increased burden among adults aged ≥65 years for PCV20 and PCV21. The incremental cost-effectiveness ratio (ICER) was $575,614 saved per QALY lost for PCV21, reflecting reduced costs but an increased disease burden. PCV20 was cost-saving in terms of cost per QALY gained, but indicated worse outcomes in terms of life years, deaths, cases, and hospitalizations. Two-dose vaccination at age 50 and 65 years improved all health outcomes but increased costs. The ICERs were $214,430/QALY gained for PCV21 and $546,811/QALY gained for PCV20. CONCLUSION: Routine pneumococcal vaccination at both age 50 and age 65 years improved health outcomes but increased costs. PCV21 yielded more favorable values than PCV20 in most scenarios.
引用
- Bletnitsky S, Leidner AJ, Kobayashi M, et al. Cost-effectiveness analysis of expanding the adult pneumococcal vaccination recommendations to include adults aged 50 years and older in the United States. Am J Prev Med. 2026. PMID: 42173413. doi:10.1016/j.amepre.2026.108412
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。